Lisata Therapeutics CEO encouraged by progress on pancreatic cancer trial
…
2,628$
-0,40%
Echtzeit-Aktienkurs LISATA THERAP.INC.DL-,001
Bid:
Ask:
Nachrichten zur LISATA THERAP.INC.DL-,001 Aktie
Lisata Therapeutics completes pancreatic cancer cohort enrollment in CENDIFOX trial
Lisata Therapeutics Inc (NASDAQ:LSTA) announced it has completed enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial.…
How does Lisata Therapeutics have a negative enterprise value?
Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech...…
Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancer
Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its…
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
…
Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript
…
Lisata Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Lisata Therapeutics reports strong 1Q performance, cash to support operations into 2026
Lisata Therapeutics Inc (NASDAQ:LSTA) has ended its first quarter of 2024 with nearly $43.3 million in cash to fund its…
Lisata Therapeutics files for $150M mixed securities shelf
…
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
…
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Achieves critical first step toward priority review voucher Achieves critical first step toward priority review voucher…
Earnings call: Lisata Therapeutics reports on clinical trials and finances By Investing.com
Earnings call: Lisata Therapeutics reports on clinical trials and finances…
Lisata Therapeutics, Inc. (LSTA) Q4 2023 Earnings Call Transcript
…